MedPath

Effect of Chlorpromazinum on schizophrenia (EChloS)

Phase 2
Conditions
Health Condition 1: F20- Schizophrenia
Registration Number
CTRI/2024/01/061210
Lead Sponsor
Dr S Sudheer Kumar
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Patients of all genders

2. Ages between 18 and 65 years of age

3. Subjects fulfilling ICD 10 diagnostic criteria of Schizophrenia. (F20)

4. Patients under Antipsychotic medication

Exclusion Criteria

1. Patients with comorbid neuro-psychiatric disorders

2. Patients with serious systemic illness.

3. Pregnant and lactating women

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Assessment of reduction in positive symptoms of Schizophrenia using Scale for Assessment of Positive Symptoms, after administration of Homoeopathic Chlorpromazinum and Individualized Homoeopathic Medicine in respective groups.Timepoint: Every month from baseline till the conclusion of the study(6th month)
Secondary Outcome Measures
NameTimeMethod
Assessment of overall improvement in the symptoms of Schizophrenia using Positive and Negative Syndrome Scale, after administration of Homoeopathic Chlorpromazinum and Individualized Homoeopathic Medicine in respective groups.Timepoint: At the baseline and end of the study(6th month);Assessment of reduction in the Side-effects of antipsychotic medications using Glasgow Anti-Psychotics Side-effect Scale after administration of Homoeopathic Chlorpromazinum and Individualized Homoeopathic Medicine in respective groups.Timepoint: Baseline, at 3rd,and conclusion of the study(6th month)
© Copyright 2025. All Rights Reserved by MedPath